Overall survival inthe OlympiA phase IIItrial of adjuvantolaparib in patientswith germlinepathogenic variantsin BRCA1/2 andhigh-risk, earlybreast cancer Charles E. GeyerJudy E. GarberRichard D. Gelber2022 год

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
статья из журнала